A novel delayed lateral flow immunoassay for enhanced detection of SARS-CoV-2 spike antigen
Issued Date
2022-10-01
Resource Type
ISSN
00263672
eISSN
14365073
Scopus ID
2-s2.0-85138196657
Pubmed ID
36125616
Journal Title
Microchimica Acta
Volume
189
Issue
10
Rights Holder(s)
SCOPUS
Bibliographic Citation
Microchimica Acta Vol.189 No.10 (2022)
Suggested Citation
Srithong P., Chaiyo S., Pasomsub E., Rengpipat S., Chailapakul O., Praphairaksit N. A novel delayed lateral flow immunoassay for enhanced detection of SARS-CoV-2 spike antigen. Microchimica Acta Vol.189 No.10 (2022). doi:10.1007/s00604-022-05467-3 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/84156
Title
A novel delayed lateral flow immunoassay for enhanced detection of SARS-CoV-2 spike antigen
Author's Affiliation
Other Contributor(s)
Abstract
A new detection strategy was developed to improve the sensitivity of a lateral flow immunoassay platform utilizing a delayed hydrophobic barrier fabricated with trimethylsilyl cellulose (TMSC). The SARS-CoV-2 spike receptor-binding domain (SARS-CoV-2 SP RBD) antigen was chosen as a model analyte to demonstrate the superior detectability of this scheme. The novel device consists of 2 separate layers, so-called delayed lateral flow immunoassay (d-LFIA). The upper layer is intended for the analyte or sample flow path, where the test solution flows freely straight to the detection zone to bind with the primary antibody. The lower layer, located just underneath, is designed for the SARS-CoV-2 spike receptor-binding domain-conjugated gold nanoparticles (SARS-CoV-2 SP RBD-AuNPs) used for producing a colorimetric signal. This layer is fabricated with a TMSC barrier to time-delay the movement of SARS-CoV-2 SP RBD-AuNPs, thus allowing the antigen to bind with the primary antibody more efficiently. This platform exhibited a 2.6-fold enhancement in the sensitivity and 9.1-fold improvement in the limit of detection (LOD) as compared with the conventional LFIA. In addition, this d-LFIA device was satisfactorily applied to accurate screening of COVID-19 patients. Graphical abstract: [Figure not available: see fulltext.]